Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Celox PPH is a **uterine hemostatic tamponade** in the form of a chitosan-covered gauze specifically designed for rapid and effective control of postpartum haemorrhage (PPH), often when conventional methods (uterotonics, antifibrinolytics, packing) have failed[1][5][6][7]. Its mechanism of action is physical and chemical: the chitosan in the gauze rapidly absorbs fluid from blood, forming a robust gel that creates a mucoadhesive plug at the site of bleeding, sealing it independently of the body’s natural clotting cascade[5][3]. This action is effective even in patients with coagulopathy or on anticoagulation therapy. The gel plug forms a physical barrier, attracts anionic red blood cells, and helps local clot formation, ultimately biodegrading through natural enzymatic breakdown into glucosamine[5]. Clinical studies have shown Celox PPH to reduce the need for hysterectomy, to be safe and inexpensive, and to have very high effectiveness (95.6–100% haemostasis) for PPH control[1][5][6][7]. Designed primarily for use following vaginal or caesarean delivery, Celox PPH can remain in place for up to 24–48 hours and is simple to apply and remove.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Celox PPH.